ArticleFrontiers in medicine2025
The impact of hormonal fluctuations and the efficacy of targeted hormonal interventions in improving macular hole outcomes.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Macular hole formation is influenced by vitreoretinal dynamics, with hormonal status playing a critical role in retinal stability. Reduced estrogen and testosterone levels in postmenopausal women and men with hypogonadism have been linked to increased macular hole severity. This study investigates the impact of hormonal fluctuations and the efficacy of targeted hormonal interventions in improving macular hole outcomes. Methods: A total of 118 participants were divided into four groups: premenopausal women ( Results: Participants with low hormone levels exhibited larger macular holes and higher progression rates. Postmenopausal women without ERT and men with hypogonadism had progression rates of 55 and 60%, respectively, while those receiving hormonal interventions showed reduced rates of 30 and 35%. Hormonal interventions significantly improved macular hole closure rates (70% in ERT and 65% in testosterone groups) and visual acuity gains (2.8 lines and 2.5 lines, respectively). Subgroup analysis indicated better outcomes in early postmenopausal women and younger men, while diabetic participants showed poorer results. Conclusion: Hormonal fluctuations significantly impact macular hole progression, and hormonal interventions can enhance closure rates and visual outcomes. Early hormonal therapy initiation is associated with better results, highlighting the potential for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.